Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-7

  Gandhi, Nirav ^a   Lenton, Richard ^b   Bhartia, Mithun ^c   Abbas, Ahmed ^d   Raju, Jessie ^b   Ramachandran, Sudarshan ^e  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e HOPE HOSPITAL   (United Kingdom)

Author keywords

ALP; ALT; Fibrates; GGT; Metabolic syndrome; PPAR ; Statins

Indexed keywords

EID: 84892551875     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-14     Document Type: Article

References (46)

1. Abbas A, Saraf S, Ramachandran S et al (2012) Factors associated with fibrate induced creatinine elevation: observations in an outpatient setting. World J Nephrol Urol 1:51-59
2. ACCORD Study Group (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563-1574
3. Aoyama T, Peters JM, Iritani N et al (1998) Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferatoractivated receptor alpha (PPARα). J Biol Chem 273:5678-5684
4. ATP3/NCEP definition (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults) (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497
5. Auwerx J, Schoonjans K, Fruchart JC et al (1996) Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb 3:81-89
6. Basaranoglu M, Acbay O, Sonsuz A (1999) A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 31:384
7. Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297-2307
8. Brown WV, Dujovne CA, Farquhar JW et al (1986) Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 6:670-678
9. Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology 142:1592-1609
10. Chinetti G, Griglio S, Antonucci M et al (1998) Activation of proliferator-activated receptor alpha and gamma induces apoptosis of human monocyte derived macrophages. J Biol Chem 273:25573-25580
11. Day CP (2006) From fat to inflammation. Gastroenterology 130:207-210
12. Day CP, James OF (1998) Steatohepatitis: a tale of two hits? Gastroenterology 114:842-845
13. Doull J, Cattley R, Elcombe C et al (1999) A cancer risk assessment of di(2- ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines. Regul Toxicol Pharmacol 29:327-357
14. Dowman JK, Tomlinson JW, Newsome PN (2010) Pathogenesis of non-alcoholic fatty liver disease. Q J Med 103:71-83
15. Dufour JF, Oneta CM, Gonvers JJ et al (2006) Swiss Association for the Study of Liver. Randomised placebo-controlled trial of ursodeoxycholic acid with vitamn E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 4:1537-1543
16. Farnier M, Bonnefous F, Debbas N et al (1994) Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 154:441-449
17. Fernandez-Miranda C, Perez-Carreras M, Colina F et al (2008) A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 40:200-205
18. Franzini M, Fornaciari I, Fierabracci V et al (2012) Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int 32:629-634
19. Frick MH, Elo O, Haapa K, Heinonen OP et al (1987) Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245
20. Harrison SA, Torqerson S, Hayashi P et al (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98:2485-2490
21. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
22. Inoue I, Shino K, Noji S et al (1998) Expression of peroxisome proliferator-activated receptor alpha (PPARα) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246:370-374
23. Jou J, Choi SS, Diehl AM (2008) Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28:370-379
24. Jun M, Foote C, Lv J et al (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375:1875-1884
25. Keech A, Simes RJ, Barter P et al (2005) FIELD Study Investigators. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet 366:1849-1861
26. Kerten S, Seydoux J, Peters JM et al (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103:1489-1498
27. Kiortsis DN, Milionis H, Bairaktari E et al (2000) Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol 56:631-635
28. Kobayashi A, Suzuki Y, Kuno H et al (2009) Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. J Toxicol Sci 34:377-387
29. Laurin J, Lindor KD, Crippin JS et al (1996) Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23:1464-1467
30. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850
31. Mathurin P, Hollebecque A, Arnalsteen L et al (2009) Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced liver disease. Gastroenterolgy 137:532-540
32. Merat S, Malekzadeh R, Sohrabi MR et al (2003) Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomised controlled study. J Hepatol 38:414-418
33. Munoz A, Guichard JP, Reginault PH (1999) Micronized fenofibrate. Atherosclerosis 110:S45-S48
34. Nakajima K (2012) Multidisciplinary pharmacotherapeutic options for nonalcoholic fatty liver disease. Int J Hepatol 2012:950693
35. Paukkeri EL, Leppanen T, Sareila U et al (2007) PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages. Br J Pharmacol 152:1081-1091
36. Poulter N (1999) The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-targets in 7,098 patients with dyslipidaemia. Br J Cardiol 6:682-685
37. Ramachandran S, Abbas A, Saraf S et al (2012) Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: findings from an outpatient clinic setting. Metab Syndr Relat Disord 10:189-194
38. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
39. Rubins HB, Robins SJ, Collins D et al (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418
40. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1308
41. Staels B, Dallongeville J, Auwerx J et al (1998a) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093
42. Staels B, Koenig W, Habib A et al (1998b) Activation of human aortic smooth muscle cells is inhibited by PPARalpha but not PPARgamma activators. Nature 393:790-793
43. The Bezafibrate Infarction Prevention (BIP) study (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102:21-27
44. The Scandinavian Simvastatin Survival Study (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
45. Walter MS, Frank MJ, Rubert M (2013) Simvastatin-activated implant surface promotes osteoblast differentiation in vitro. J Biomater Appl [Epub ahead of print]
46. Zelber-Sagi S, Halpern Z, Webb M et al (2005) Is non-alcoholic fatty liver disease (NAFLD) an independent predictor of the metabolic syndrome? Hepatology 42:617